Ponatinib efficacy and safety in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor (TKI) failure: Results from a phase 2 study.

被引：0
|
作者：
Heinrich, Michael C.
von Mehren, Margaret
Demetri, George D.
Fletcher, Jonathan A.
Sun, Jichao G.
Kerstein, David
Conlan, Maureen G.
George, Suzanne
机构：
[1] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA
[3] Temple Univ Hlth Syst, Fox Chase Canc Ctr, Philadelphia, PA USA
[4] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA
[5] Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Boston, MA USA
[6] Ariad Pharmaceut Inc, Cambridge, MA USA
[7] ARIAD Pharmaceut Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10535
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase 2 study of ponatinib in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after failure of tyrosine kinase inhibitor (TKI) therapy: Initial report.
    Heinrich, Michael C.
    vonMehren, Margaret
    Demetri, George D.
    Fletcher, Jonathan A.
    Sun, Jichao
    Hodgson, J. Graeme
    Rivera, Victor M.
    Turner, Christopher D.
    George, Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Real-world outcomes of ponatinib in treatment of advanced gastrointestinal Stromal tumors (GIST) after tyrosine kinase rihibitor (TKI) failure.
    Heinrich, Michael C.
    McGarry, Lisa
    Kerstein, David
    Huang, Hui
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Analysis of serum protein biomarkers and circulating tumor (ct) DNA for activity of dovitinib in patients (pts) with tyrosine kinase inhibitor (TKI)-refractory gastrointestinal stromal tumors (GIST).
    Yoo, Changhoon
    Ryu, Min-Hee
    Ryoo, Baek-Yeol
    Park, Sook Ryun
    Yoon, Shinkyo
    Na, Young-Soon
    Kang, Yoon-Koo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] A retrospective natural history study of patients (pts) with PDGFRα D842V mutant advanced gastrointestinal stromal tumor (GIST) previously treated with a tyrosine kinase inhibitor (TKI).
    von Mehren, Margaret
    Heinrich, Michael C.
    Shi, Hongliang
    McNamara, Patrick
    Mamlouk, Khalid Kevin
    Boral, Anthony
    George, Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma.
    Qiu, Haibo
    Zhou, Zhi-wei
    Zhou, Ye
    Chen, Jie
    Wan, Xiangbin
    Li, Ning
    Tao, Kaixiong
    Li, Yong
    Wu, Xin
    Chen, Zi
    Liu, Lihui
    Yang, Chen
    Men, Lichuang
    Wang, Hengbang
    Liang, Eric
    Wang, Cunlin
    Jiang, Lixin
    Yang, Dajun
    Zhai, Yifan
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers
    George, Suzanne
    von Mehren, Margaret
    Fletcher, Jonathan A.
    Sun, Jichao
    Zhang, Sen
    Pritchard, Justin R.
    Hodgson, John Graeme
    Kerstein, David
    Rivera, Victor M.
    Haluska, Frank G.
    Heinrich, Michael C.
    CLINICAL CANCER RESEARCH, 2022, 28 (07) : 1268 - 1276
  • [7] The efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: A multicenter, retrospective study.
    Yang, Weili
    Qian, Haoran
    Yang, Litao
    Wang, Pengfei
    Qian, Hailong
    Chu, Binbin
    Liu, Zhuo
    Sun, Jingyu
    Wu, Dan
    Sun, Lifeng
    Zhou, Wenqiang
    Hu, Jingwei
    Chen, Xiaolei
    Shou, Chunhui
    Ruan, Lingxiang
    Yu, Jiren
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 800 - 800
  • [8] A phase 2 trial of PF-00299804 (PF299), an oral irreversible HER tyrosine kinase inhibitor (TKI), in patients (pts) with advanced NSCLC after failure of prior chemotherapy and erlotinib: preliminary efficacy and safety results
    Janne, Pasi A.
    Reckamp, Karen
    Koczywas, Marianna
    Camidge, David R.
    Engelman, Jeffery A.
    Khuri, Fadlo
    Rajan, Arun
    Gadgeel, Shirish
    Taylor, Ian
    Liang, Jane
    O'Connell, Joseph
    Giaccone, Giuseppe
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S293 - S294
  • [9] Antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST)
    Qiu, Haibo
    Zhou, Zhi-Wei
    Zhou, Ye
    Wan, Xiangbin
    Li, Ning
    Tao, Kaixiong
    Li, Yong
    Wu, Xin
    Chen, Zi
    Liu, Lihui
    Men, Lichuang
    Wang, Hengbang
    Liang, Eric
    Wang, Cunlin
    Jiang, Lixin
    Yang, Dajun
    Xu, Rui-Hua
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Comparative Efficacy and Safety of Different Regimens of Advanced Gastrointestinal Stromal Tumors After Failure Prior Tyrosine Kinase Inhibitors: A Network Meta-Analysis
    Xue Zhang
    Yueqin Liang
    Yanhua Li
    Jiafu Yin
    Advances in Therapy, 2021, 38 : 399 - 412
12345